At Ova
At Ova
Atova ®
Tablet
Description
Atova is a preparation of Atorvastatin Calcium, which is a synthetic lipid
lowering agent. It is an inhibitor of 3-hydroxy-3-methyl-glutaryl-
coenzyme A (HMG-CoA). This enzyme catalyses the conversion of
HMG-CoA to mevatonate, an early and rate limiting step in the synthesis
of cholesterol.
Indications
Atova is indicated as an adjunct to diet to reduce elevated total cholesterol
(C), low density lipoprotein-cholesterol (LDL-C), apolipoprotein B and
triglyceride (TG) levels in patients with primary hypercholesterolaemia
(heterozygous familial and non familial) and mixed dyslipidaemia
(Fredrickson Types lla and llb).
42
T H E R A P E U T I C I N D E X
Yes Yes or No > 130 c (> 3.4) < 100 (< 2.6)
b. Other risk factors for coronary heart disease (CHD) include : age (males > 45 years;
females > 55 years or premature menopause without estrogen replacement therapy);
family history of premature CHD; current cigarette smoking; hypertension;
confirmed HDL-C < 35 mg/dl (< 0.91 mmol/L); and diabetes mellitus. Subtract 1
risk factor if HDL-C is > 60 mg/dl (> 1.6 mmol/L).
c. In CHD patients with LDL-C levels 100 to 129 mg/dl, the physician should exercise
clinical judgement in deciding whether to initiate drug treatment.
43
T H E R A P E U T I C I N D E X
Since the goal of treatment is to lower LDL-C, the LDL-C levels should
be used to initiate and assess treatment response. Only if LDL-C levels
are not available, total-C should be used to monitor therapy.
Patients with renal insufficiency : Renal disease has no influence on the plasma
concentrations or lipid effects of Atorvastatin; thus no adjustment of
dose is required. Haemodialysis is not expected to significantly enhance
the clearance of Atorvastatin since the drug is extensively bound to
plasma proteins.
Contraindications
Hypersensitivity to any component of this medication. Active liver
disease or unexplained persistent elevations of serum transaminases
exceeding three times the upper limit of normal.
Precautions
Rhabdomyolysis with acute renal failure secondary to myoglobinuria has
been reported with other drugs in this class. Atorvastatin may cause an
44
T H E R A P E U T I C I N D E X
The risk of myopathy during treatment with other drugs in this class is
increased with concurrent administration of Cyclosporin, fibric acid
derivatives, Erythromycin, Niacin, or azole anti-fungals. Patients should
be advised to report promptly any unexplained muscle pain, tenderness or
weakness, particularly if accompanied by malaise or fever.
Side Effects
Atorvastatin is generally well tolerated. Adverse effects reported
commonly include constipation, flatulence, dyspepsia, abdominal pain,
headache, nausea, myalgia, diarrhoea, asthenia and insomnia.
45
T H E R A P E U T I C I N D E X
Commercial Packs
Atova® 10 Tablet : Box containing 30 tablets in 3 x 10’s blister strip, each
tablet contains Atorvastatin Calcium INN equivalent to Atorvastatin 10 mg.
46